文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

瑞扎芬净与卡泊芬净治疗ICU念珠菌血症或侵袭性念珠菌病:ReSTORE与STRIVE随机试验汇总分析

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials.
PubMed 文献 · Crit Care · 2024-10-28
一句话结论ICU念珠菌血症/侵袭性念珠菌病患者中,瑞扎芬净第30天全因死亡率34.8% vs 卡泊芬净25.4%,血培养转阴中位时间18 vs 38小时(分层log-rank P=0.001,名义性)。

本文为STRIVE(2期)与ReSTORE(3期)随机双盲试验的事后汇总分析,纳入随机分组时在ICU的念珠菌血症和/或侵袭性念珠菌病成人患者113例(瑞扎芬净46例,卡泊芬净67例)。瑞扎芬净为静脉400 mg负荷剂量后200 mg每周一次,卡泊芬净为70 mg负荷剂量后50 mg每日一次,均≤4周。第30天全因死亡率瑞扎芬净34.8% vs 卡泊芬净25.4%;第5天和第14天真菌学清除率分别为78.3%和71.7% vs 59.7%和65.7%;血培养转阴中位时间18 vs 38小时(分层log-rank P=0.001,名义性,未校正多重比较)。两组安全性相似,因治疗中出现的不良事件停药分别为17.4% vs 29.9%。

要点

  • ICU念珠菌血症/侵袭性念珠菌病患者中,瑞扎芬净第30天全因死亡率34.8%(46例)vs 卡泊芬净25.4%(67例)。
  • 血培养转阴中位时间瑞扎芬净18小时(IQR 12.6-43.0)vs 卡泊芬净38小时(IQR 15.9-211.3),分层log-rank P=0.001(名义性,未校正多重比较)。
  • 第5天真菌学清除率瑞扎芬净78.3% vs 卡泊芬净59.7%;第14天分别为71.7% vs 65.7%。
  • 因治疗中出现的不良事件停药:瑞扎芬净17.4% vs 卡泊芬净29.9%;两组安全性特征相似。
  • 归因于念珠菌血症/侵袭性念珠菌病的死亡:瑞扎芬净2例 vs 卡泊芬净1例。

适用人群与场景

  • 随机分组时在ICU的成人患者,具有念珠菌血症和/或侵袭性念珠菌病的全身症状及随机分组前≤96小时血液或正常无菌部位真菌学确认。
  • 纳入STRIVE和ReSTORE两项随机双盲试验的294例患者中,随机分组时在ICU者113例(瑞扎芬净46例,卡泊芬净67例)。
  • 基线时每组约30%患者存在肾功能受损和/或急性生理与慢性健康评估II评分≥20;卡泊芬净组1例患者基线中性粒细胞减少。

处置流程与药物剂量

  • 瑞扎芬净:静脉400 mg负荷剂量,之后200 mg每周一次,疗程≤4周。
  • 卡泊芬净:静脉70 mg负荷剂量,之后50 mg每日一次,疗程≤4周。

研究设计与关键结果

  • 研究类型:2期STRIVE与3期ReSTORE随机双盲试验的事后汇总分析;随机分组时在ICU的念珠菌血症和/或侵袭性念珠菌病患者113例(瑞扎芬净46例,卡泊芬净67例)。
  • 主要终点第30天全因死亡率:瑞扎芬净34.8% vs 卡泊芬净25.4%。
  • 第5天真菌学清除率:瑞扎芬净78.3% vs 卡泊芬净59.7%;第14天:瑞扎芬净71.7% vs 卡泊芬净65.7%。
  • 血培养转阴中位时间:瑞扎芬净18小时(IQR 12.6-43.0)vs 卡泊芬净38小时(IQR 15.9-211.3),分层log-rank P=0.001(名义性,未校正多重比较)。
  • 归因于念珠菌血症/侵袭性念珠菌病的死亡:瑞扎芬净2例 vs 卡泊芬净1例。
  • 安全性特征两组相似;因治疗中出现的不良事件停药:瑞扎芬净17.4% vs 卡泊芬净29.9%。
  • 瑞扎芬净初始400 mg剂量后的暴露在随机分组时在ICU的患者(n=50)与非ICU患者(n=117)之间相当。

证据类型、等级与局限

  • 证据类型:2期STRIVE与3期ReSTORE随机双盲试验的事后汇总分析。
  • 血培养转阴时间的分层log-rank P=0.001为名义性,未校正多重比较。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,瑞扎芬净在主要为非中性粒细胞减少的念珠菌血症和/或侵袭性念珠菌病危重患者中耐受良好且有效。
  • 作者认为,该分析为瑞扎芬净在ICU人群中的疗效和安全性提供了额外见解。

指南或共识出处

  • STRIVE(2期)与ReSTORE(3期)随机双盲试验

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with candidaemia and/or invasive candidiasis (IC) in the intensive care unit (ICU) at randomisation.

METHODS: STRIVE and ReSTORE were randomised double-blind trials in adults with systemic signs and mycological confirmation of candidaemia and/or IC in blood or a normally sterile site ≤ 96 h before randomisation. Data were pooled for patients in the ICU at randomisation who received intravenous rezafungin (400 mg loading dose then 200 mg once weekly) or caspofungin (70 mg loading dose then 50 mg once daily) for ≤ 4 weeks. Outcomes were Day 30 all-cause mortality (primary outcome), Day 5 and 14 mycological eradication, time to negative blood culture, mortality attributable to candidaemia/invasive candidiasis, safety, and pharmacokinetics.

RESULTS: Of 294 patients in STRIVE/ReSTORE, 113 were in the ICU at randomisation (rezafungin n = 46; caspofungin n = 67). At baseline, ~ 30% of patients in each group had impaired renal function and/or an Acute Physiologic Assessment and Chronic Health Evaluation II score ≥ 20. One patient (in the caspofungin group) was neutropenic at baseline. Day 30 all-cause mortality was 34.8% for rezafungin versus 25.4% for caspofungin. Day 5 and 14 mycological eradication was 78.3% and 71.7% for rezafungin versus 59.7% and 65.7% for caspofungin, respectively. Median time to negative blood culture was 18 (interquartile range, 12.6-43.0) versus 38 (interquartile range, 15.9-211.3) h for rezafungin versus caspofungin (stratified log-rank P = 0.001; nominal, not adjusted for multiplicity). Candidaemia/IC-attributable deaths occurred in two rezafungin patients versus one caspofungin patient. Safety profiles were similar between groups. Overall, 17.4% (rezafungin) versus 29.9% (caspofungin) of patients discontinued due to treatment-emergent adverse events. Rezafungin exposure following the initial 400-mg dose was comparable between patients in the ICU at randomisation (n = 50) and non-ICU patients (n = 117).

CONCLUSIONS: Rezafungin was well tolerated and efficacious in critically ill, mainly non-neutropenic patients with candidaemia and/or IC. This analysis provides additional insights into the efficacy and safety of rezafungin in the ICU population.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Honoré PM, Girardis M, Kollef M, et al. Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. Crit Care. 2024. PMID: 39468640. doi:10.1186/s13054-024-05117-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。